RNS Number : 4668I
Fusion Antibodies PLC
16 October 2024
 

16 October 2024

  

Fusion Antibodies plc

("Fusion" or the "Company")

 

Director/PDMR Shareholding

 

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, has been notified that Adrian Kinkaid, Chief Executive Officer of Fusion, has purchased 83,728 ordinary shares of 4 pence each in the Company ("Ordinary Shares") at a price of 4.185 pence per Ordinary Share. Following this purchase, Adrian Kinkaid directly holds 750,000 Ordinary Shares, representing approximately 0.79 per cent. of the Company's issued share capital. 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Adrian Kinkaid

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Fusion Antibodies plc

b)

LEI

213800KBAYRC9VOQ9V39

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

ordinary shares of 4p each in Fusion Antibodies plc

 

 

Identification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16

b)

Nature of the transaction

Purchase of Ordinary Shares

 

c)

Price(s) and volume(s)

 

 

 

 Price(s)

Volume(s)

4.185p

83,728

d)

Aggregated information

- Aggregated volume

- Price

 

-      see above

-      see above

e)

Date of the transaction

16 October 2024

f)

Place of the transaction

XLON, London Stock Exchange

 

Enquiries: 

 

Fusion Antibodies plc

           www.fusionantibodies.com

Adrian Kinkaid, Chief Executive Officer

Stephen Smyth, Chief Financial Officer

Via Walbrook PR



Fusion Antibodies interactive investor hub

https://investorhub.fusionantibodies.com/

 

 


Allenby Capital Limited

Tel: +44 (0) 20 3328 5656 

James Reeve/Vivek Bhardwaj (Corporate Finance)

Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)




 


Shard Capital Partners LLP


Damon Heath (Joint Broker)

Tel: +44 (0) 207 186 9952



 


Walbrook PR

          Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com

Anna Dunphy

                             Mob: +44 (0)7876 741 001

 

About Fusion Antibodies plc

 

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

 

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

 

The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.

 

Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process. 

 

The global monoclonal antibody therapeutics market was valued at $186 billion in 2021 and is forecast to surpass $445 billion in 2028, an increase at a CAGR of 13.2 per cent. for the period 2022 to 2028. Approximately 150 monoclonal antibody therapies are approved and marketed globally as of June 2022 with the top four antibody drugs each having sales of more than $3 bn in 2021.  

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFFEFEMELSEES
Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Fusion Antibodies Charts.
Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Fusion Antibodies Charts.